A Pathogenic NRAS c.38G>A (p.G13D) Mutation in RARA Translocation-negative Acute Promyelocytic-like Leukemia with Concomitant Myelodysplastic Syndrome

An acute promyelocytic leukemia (APL) patient not demonstrating the retinoic acid receptor α (RARA) translocation is rare. A 76-year-old man was diagnosed with myelodysplastic syndrome (MDS). After a year, abnormal promyelocytes were detected with pancytopenia and disseminated intravascular coagulopathy. Morphologically, the patient was diagnosed with APL; however, a genetic examination failed to detect RARA translocation. Thereafter, whole-genome sequencing revealed an NRAS missense mutation [c.38G>A (p.G13D)]. This mutation was not detected in posttreatment bone marrow aspirate, despite residual MDS. Few reports are available on similar cases. Furthermore, the NRAS c.38G>A mutation may be a novel pathogenic variant exacerbating RARA translocation-negative acute promyelocytic-like leukemia.

[1]  E. Estey,et al.  Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. , 2019, Blood.

[2]  S. Miyano,et al.  Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. , 2017, Blood.

[3]  C. Posch,et al.  Searching for the Chokehold of NRAS Mutant Melanoma. , 2016, The Journal of investigative dermatology.

[4]  S. Miyano,et al.  Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia , 2016, Leukemia.

[5]  N. Socci,et al.  Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity , 2015, Nature Biotechnology.

[6]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[7]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[8]  Joshua F. McMichael,et al.  The Origin and Evolution of Mutations in Acute Myeloid Leukemia , 2012, Cell.

[9]  F. Speleman,et al.  Refinement of 1p36 Alterations Not Involving PRDM16 in Myeloid and Lymphoid Malignancies , 2011, PloS one.

[10]  Ken Chen,et al.  Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. , 2011, JAMA.

[11]  A. Acquaviva,et al.  Germ‐line mutation of the NRAS gene may be responsible for the development of juvenile myelomonocytic leukaemia , 2009, British journal of haematology.

[12]  Ken Chen,et al.  Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.

[13]  K. Koike,et al.  Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. , 2007, Blood.

[14]  T. Naoe,et al.  A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. , 2006, Blood.

[15]  T. Ley,et al.  Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. , 1997, Blood.

[16]  V. Najfeld,et al.  Myelodysplastic syndrome transforming to acute promyelocytic‐like leukemia with trisomy and rearrangement of chromosome II , 1994 .

[17]  Christine Chomienne,et al.  The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR , 1991, Cell.

[18]  C. Marshall,et al.  Amino-acid substitutions at codon 13 of the N-ras oncogene in human acute myeloid leukaemia , 1985, Nature.

[19]  F. Ogushi,et al.  Acute myeloid leukemia with myelodysplasia-related changes mimicking acute promyelocytic leukemia. , 2011, Internal medicine.